There is plenty of interesting news floating about
Post# of 30067
(Total Views: 686)
Posted On: 03/30/2019 8:34:05 PM
There is plenty of interesting news floating about.... if one is so inclined to do some DD.
Amarantus
Elto Pharma
Coeptis Pharmaceuticals
IDEA Pharma
Kitov Pharma
Consensi™
MIKE REA - what are his connections
connections of the former Kadmon
"We are especially excited about working with the organizations being established around each of Amarantus' pipeline products as we will be able to create value for Amarantus not only with its portfolio, but also with the complementary assets being aggregated within each of those organizations, beginning with Coeptis' recently approved product Consensi®."
"Dual benefits to Amarantus shareholders should accrue from its' participation as a shareholder in the eltoprazine opportunity, as well as in Coeptis' entire product pipeline. Coeptis recently completed a transaction to gain rights to an FDA-approved drug it expects to launch later in 2019, thereby potentially providing cash flow to support eltoprazine's further development, as well as possibly mitigating Amarantus-owned equity dilution in Coeptis down the road."
- Breakthrough Diagnostics, Inc. -" We expect the Joint Venture transaction to be completed in the first quarter of 2019."
"We intend to make determinations and begin executing on Cutanogen and MANF plans in the first half of 2019."
"A jug fills drop by drop"
Buddha
Much Aloha
Amarantus
Elto Pharma
Coeptis Pharmaceuticals
IDEA Pharma
Kitov Pharma
Consensi™
MIKE REA - what are his connections
connections of the former Kadmon
"We are especially excited about working with the organizations being established around each of Amarantus' pipeline products as we will be able to create value for Amarantus not only with its portfolio, but also with the complementary assets being aggregated within each of those organizations, beginning with Coeptis' recently approved product Consensi®."
"Dual benefits to Amarantus shareholders should accrue from its' participation as a shareholder in the eltoprazine opportunity, as well as in Coeptis' entire product pipeline. Coeptis recently completed a transaction to gain rights to an FDA-approved drug it expects to launch later in 2019, thereby potentially providing cash flow to support eltoprazine's further development, as well as possibly mitigating Amarantus-owned equity dilution in Coeptis down the road."
- Breakthrough Diagnostics, Inc. -" We expect the Joint Venture transaction to be completed in the first quarter of 2019."
"We intend to make determinations and begin executing on Cutanogen and MANF plans in the first half of 2019."
"A jug fills drop by drop"
Buddha
Much Aloha
(2)
(1)